PRX Related FDA
-
Par Pharma (PRX) Begins U.S. Shipments of Generic Symbyax (LLY)
-
Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too
-
Somaxon (SOMX), Mylan (MYL), Par Pharma (PRX) Enter Silenor Settlement
-
Par Pharma's (PRX) Formulations Unit Receives First FDA Approval for Labetalol
-
Teva (TEVA), Par Pharma (PRX) said to lose bid to sell the generic form of Glaxo's (GSK) Lovaza
-
Horizon Pharma (HZNP) Files Patent Infringement Suit Against Par Pharma (PRX) Over DUEXIS Tabs
-
Horizon Pharma (HZNP) Says Par Pharma (PRX) Files ANDA for Generic DUEXIS
-
Par Pharmaceutical (PRX) Falls On Allegations of Drug-Switching Scheme
-
Intellipharmaceutics (IPCI), Par Pharma (PRX) Expand Generic Focalin XR Development Agreement
-
POZEN (POZN) Gets Preliminary Injunction for Generic Treximet
-
Par Pharma (PRX) Commences Shipments of Generic Lotrel
-
MonoSol Rx Announces Partner Strativa Pharma Gets U.S. FDA Approval for Zuplenz (PRX)
-
Par Pharma (PRX) Subsidiary Gets U.S. FDA Approval for Zuplenz
-
Par Pharma (PRX) Begins Shipment of Generic Zegerid (SNTS)
-
Warner Chilcott (WCRX) Gets Paragraph IV Certification from Par Pharma (PRX) Regarding Generic ASACOL
-
Par Pharma (PRX) Partner Settles with Merck (MRK) Over ZETIA Patents
-
Par Pharma (PRX) and Glenmark Generics Sign Licensing Agreement for Generic Zetia
-
Par Pharma (PRX) Subsidiary Announces Approval for Oravig from U.S. FDA
-
Santarus (SNTS) Receives Unfavorable Ruling in ZEGERID Patent Litigation (PRX)
-
Par Pharma (PRX) Enters Agreement with sanofi-aventis (SNY) to Settle Patent Litigation Over Generic Eloxatin(R)
-
Par Pharma (PRX) Subsidiary Strativa Receives Response Letter from U.S. FDA for Zuplenz
-
Par Pharma (PRX) Receives Final U.S. FDA Approval for Tramadol ER Doses
-
Par Pharma (PRX) Receives Final Approval to Market Generic Catapres TTS(R); FDA Accepts Application for Miconazole Lauriad(R)
-
Par Pharmaceutical (PRX) Wins on Invalidity in Ultram ER Litigation
-
Par Pharmaceutical (PRX) Receives FDA Approval for Generic Marinol
-
Par Pharmaceutical (PRX) Licenses Rights to Loramyc
-
Par Pharmaceutical (PRX) Receives Final FDA Approval for Ondansetron ODT
-
Spectrum Pharmaceuticals (SPPI) Announces Patent Litigation with GlaxoSmithKline (GSK) has been Dismissed
-
AstraZeneca (AZN) Announces Distribution Agreement with Par Pharma (PRX); Updates FY Guidance
-
Par Pharmaceutical (PRX) Announces Settlement with GlaxoSmithKline (GSK)
-
NovaDel (NVD) Receives FDA Approval of NitroMist
-
Par Pharmaceutical (PRX) Receives FDA Approval for Generic Pravachol
-
Par Pharmaceutical (PRX) Receives Patent Relating to Megace ES 625 mg/5 mL Oral Suspension
-
Par Pharmaceutial (PRX) Subsidiary Receives Final FDA Approval For Polyethylene Glycol 3350 NF
-
PRX Halts Shipments of Fluticasone After U.S. Court Grants GSK Temporary Restraining Order
-
PRX Received Final Approval for Generic Cefzil
-
PRX Receives Final Approval to Market Generic Dostinex
-
BDY In Licensing Agreement With PRX
-
PRX Announces FDA Final Approval
-
PRX Gets Approval and Marketing Exclusivity for Ondanestron Hydrochloride
-
PRX Announces FDA Approval For Leflunomide Tablets
-
PRX Gets Final Approval for Oral Clonazepam
-
PRX Ends AVNC Partnership
-
PRX Gets FDA Okay for Megace ES
-
PRX Gets Tentative FDA Approval for Ondansetron Hydrochloride
-
AVNC/PRX Strep Throat Trial Failed to Achieve Endpoints
-
PRX Receives Approval to Market Generic Ultracet
-
FDA Extends PDUFA Date For PRX's Megace
Back to PRX Stock Lookup
